Finnerty Thomas
Known title: EVP, Human ResourcesCIK: 0001720871
Associated companies
Transaction History
| ANIK | ▲ Buy | Option Exercise | 2,548 | $0 | 3/9/2022 | View on chart |
| ANIK | ▼ Sell | Tax Withholding | 748 | $20K | 3/9/2022 | View on chart |
| ANIK | ▲ Buy | Option Exercise | 3,000 | $0 | 2/26/2022 | View on chart |
| ANIK | ▼ Sell | Tax Withholding | 881 | $28K | 2/26/2022 | View on chart |
| ANIK | ▲ Buy | Option Exercise | 2,834 | $0 | 2/25/2022 | View on chart |
| ANIK | ▼ Sell | Tax Withholding | 832 | $27K | 2/25/2022 | View on chart |
| ANIK | ▲ Buy | Grant | 10,125 | $0 | 2/9/2022 | View on chart |
| ANIK | ▼ Sell | Tax Withholding | 3,149 | $97K | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
ANIK Stock Moves Amid Broader Biotech Sector News
Recent news coverage focuses on clinical trial results from other biotech companies like Merck and Amgen, rather than specific new developments for Anika Therapeutics. One article examines whether ANIK is outperforming other medical stocks this year. The stock currently trades within its 52-week range, with analysts maintaining a target price of $21.00.
ANIK Stock Moves Amid Broader Biotech Sector News. Recent news coverage focuses on clinical trial results from other biotech companies like Merck and Amgen, rather than specific new developments for Anika Therapeutics. One article examines whether ANIK is outperforming other medical stocks this year. The stock currently trades within its 52-week range, with analysts maintaining a target price of $21.00.